Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Alnylam Pharmaceuticals, Inc. (ALNY) vs Revolution Medicines, Inc. (RVMD)

Alnylam Pharmaceuticals, Inc. and Revolution Medicines, Inc. are both Biotechnology companies. Revolution Medicines, Inc. is the larger, with a market value of $42.9B against $31.2B — 1.4× the size. Revolution Medicines, Inc. has negative trailing earnings, so its P/E is not meaningful; Alnylam Pharmaceuticals, Inc. trades at 43.6×. Alnylam Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 95.1% against −8.81%. Alnylam Pharmaceuticals, Inc. has the higher net margin (16.1% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Alnylam Pharmaceuticals, Inc. leads on 14 and Revolution Medicines, Inc. on 3.

Valuation

Metric ALNY RVMD Biotechnology median
P/E 43.62 n/m 7.88
P/S 7.12 1,606.35 11.47
P/B 25.25 16.59 2.52
Price to free cash flow 41.71 n/m 21.16
EV/EBITDA 30.25 n/m 0.74
EV/Sales 6.64 1,498.51 10.73
Earnings yield 2.29% (4.30%) (28.84%)
Free cash flow yield 2.40% (2.85%) (23.03%)

Profitability

Metric ALNY RVMD Biotechnology median
Gross margin 79.65% 35.06% 65.16%
Operating margin 20.81% 0.00% 0.00%
Net margin 16.13% 0.00% 0.00%
Free cash flow margin 17.07% 0.00% 0.00%
Return on equity 96.55% (79.09%) (57.72%)
Return on assets 15.30% (52.37%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ALNY RVMD Biotechnology median
Revenue growth (TTM) 95.14% (8.81%) 5.64%
EPS growth (last fiscal year) 206.88% (66.20%) —
Revenue growth, 5-year CAGR 49.77% (10.50%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALNY RVMD Biotechnology median
Debt to equity 0.75 0.40 0.00
Current ratio 3.05 11.38 4.73
Net debt to EBITDA (3.41) 1.47 0.96

Dividend

Metric ALNY RVMD Biotechnology median
Dividend yield 2.52% — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ALNY RVMD Biotechnology median
Market cap 31.16b 42.88b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack